FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1495830587> ?p ?o ?g. }

• W1495830587 endingPage "871" @default.
• W1495830587 startingPage "859" @default.
• W1495830587 abstract "Endometrial carcinoma (EC) is a common female cancer, treated mainly by surgery and adjuvant radiotherapy. Relapse following treatment is associated with increased risk of metastases. Hypoxia, a common microenvironment in solid tumors, correlates with malignant progression, rendering tumors resistant to ionizing therapy. Hence, we assessed here the immunohistochemical expression of hypoxia-inducible factor-1α (HIF-1α) and members of the NF-κB family in 82 primary EC and 10 post-radiation recurrences of EC. Post-radiation recurrences were highly hypoxic, with a higher expression of HIF-1α and also RelA (p65) and p52 when compared with primary EC. We next investigated the effects of hypoxia on EC cell lines. We found that EC cell lines are highly resistant to hypoxia-induced apoptosis. We thus focused on the molecular mechanisms involved in conferring hypoxic cell death resistance. We show that in addition to the classical NF-κB, hypoxia activates the alternative NF-κB pathway. To characterize the upstream kinases involved in the activation of these pathways, we used lentiviral-mediated knockdown and mouse embryonic fibroblasts lacking IKKα and IKKβ kinases. Both IKKα and IKKβ kinases are required for RelA (p65) and p100 accumulation, whereas p52 processing under hypoxia is IKKα dependent. Furthermore, Ishikawa endometrial cell line harboring either RelA (p65) or p52 short-hairpin RNA was sensitive to hypoxia-induced cell death, indicating that, in addition to the known prosurvival role of RelA (p65) under hypoxia, alternative NF-κB pathway also enhances hypoxic survival of EC cells. Interestingly, although HIF-1α controlled classical NF-κB activation pathway and survival under hypoxia through RelA (p65) nuclear accumulation, the alternative pathway was HIF-1α independent. These findings have important clinical implications for the improvement of EC prognosis before radiotherapy." @default.
• W1495830587 created "2016-06-24" @default.
• W1495830587 creator A5006229278 @default.
• W1495830587 creator A5028017064 @default.
• W1495830587 creator A5032710158 @default.
• W1495830587 creator A5038889709 @default.
• W1495830587 creator A5047062925 @default.
• W1495830587 creator A5048002647 @default.
• W1495830587 creator A5049702399 @default.
• W1495830587 creator A5052359409 @default.
• W1495830587 creator A5052765544 @default.
• W1495830587 creator A5062508429 @default.
• W1495830587 creator A5063962303 @default.
• W1495830587 creator A5069925431 @default.
• W1495830587 date "2011-06-01" @default.
• W1495830587 modified "2023-10-18" @default.
• W1495830587 title "Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner" @default.
• W1495830587 cites W1493048246 @default.
• W1495830587 cites W1501881225 @default.
• W1495830587 cites W1799143857 @default.
• W1495830587 cites W1976443579 @default.
• W1495830587 cites W1976783896 @default.
• W1495830587 cites W1976857316 @default.
• W1495830587 cites W1980415233 @default.
• W1495830587 cites W1980768491 @default.
• W1495830587 cites W1981115336 @default.
• W1495830587 cites W1987531976 @default.
• W1495830587 cites W1991868611 @default.
• W1495830587 cites W1999692789 @default.
• W1495830587 cites W2009211112 @default.
• W1495830587 cites W2014518336 @default.
• W1495830587 cites W2015344488 @default.
• W1495830587 cites W2015883486 @default.
• W1495830587 cites W2021242696 @default.
• W1495830587 cites W2027680551 @default.
• W1495830587 cites W2043150560 @default.
• W1495830587 cites W2051644361 @default.
• W1495830587 cites W2062764368 @default.
• W1495830587 cites W2063512271 @default.
• W1495830587 cites W2069356140 @default.
• W1495830587 cites W2071318863 @default.
• W1495830587 cites W2073659616 @default.
• W1495830587 cites W2077688090 @default.
• W1495830587 cites W2085685524 @default.
• W1495830587 cites W2087604644 @default.
• W1495830587 cites W2103154710 @default.
• W1495830587 cites W2103944436 @default.
• W1495830587 cites W2106123852 @default.
• W1495830587 cites W2106877484 @default.
• W1495830587 cites W2124990153 @default.
• W1495830587 cites W2125096092 @default.
• W1495830587 cites W2125784233 @default.
• W1495830587 cites W2129579134 @default.
• W1495830587 cites W2140855200 @default.
• W1495830587 cites W2144625075 @default.
• W1495830587 cites W2147921405 @default.
• W1495830587 cites W2159722075 @default.
• W1495830587 cites W2162121911 @default.
• W1495830587 cites W2167361262 @default.
• W1495830587 cites W2170488331 @default.
• W1495830587 cites W2316580498 @default.
• W1495830587 doi "https://doi.org/10.1038/labinvest.2011.58" @default.
• W1495830587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21537326" @default.
• W1495830587 hasPublicationYear "2011" @default.
• W1495830587 type Work @default.
• W1495830587 sameAs 1495830587 @default.
• W1495830587 citedByCount "30" @default.
• W1495830587 countsByYear W14958305872012 @default.
• W1495830587 countsByYear W14958305872013 @default.
• W1495830587 countsByYear W14958305872014 @default.
• W1495830587 countsByYear W14958305872015 @default.
• W1495830587 countsByYear W14958305872016 @default.
• W1495830587 countsByYear W14958305872017 @default.
• W1495830587 countsByYear W14958305872020 @default.
• W1495830587 countsByYear W14958305872021 @default.
• W1495830587 countsByYear W14958305872022 @default.
• W1495830587 countsByYear W14958305872023 @default.
• W1495830587 crossrefType "journal-article" @default.
• W1495830587 hasAuthorship W1495830587A5006229278 @default.
• W1495830587 hasAuthorship W1495830587A5028017064 @default.
• W1495830587 hasAuthorship W1495830587A5032710158 @default.
• W1495830587 hasAuthorship W1495830587A5038889709 @default.
• W1495830587 hasAuthorship W1495830587A5047062925 @default.
• W1495830587 hasAuthorship W1495830587A5048002647 @default.
• W1495830587 hasAuthorship W1495830587A5049702399 @default.
• W1495830587 hasAuthorship W1495830587A5052359409 @default.
• W1495830587 hasAuthorship W1495830587A5052765544 @default.
• W1495830587 hasAuthorship W1495830587A5062508429 @default.
• W1495830587 hasAuthorship W1495830587A5063962303 @default.
• W1495830587 hasAuthorship W1495830587A5069925431 @default.
• W1495830587 hasBestOaLocation W14958305871 @default.
• W1495830587 hasConcept C100175707 @default.
• W1495830587 hasConcept C104317684 @default.
• W1495830587 hasConcept C123298856 @default.
• W1495830587 hasConcept C173396325 @default.
• W1495830587 hasConcept C178790620 @default.
• W1495830587 hasConcept C184235292 @default.
• W1495830587 hasConcept C185592680 @default.

• next